| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC0846 |
| Trial ID | ChiCTR2000028923 |
| Disease | B-Cell Lymphoma |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Study for the Efficacy and Safety of CD19 and CD22 CAR-T Cells Immunotherapy for Relapse /Refractory B-Line Cell Lymphoma Patients |
| Year | 2020 |
| Country | China |
| Company sponsor | The Third Affiliated Hospital of Kunming Medical University |
| Cohort 1 | |||||||
|
|||||||